Background: In immunosuppressive therapy administered after organ transplantation, therapeutic drug monitoring (TDM) of tacrolimus must be performed frequently because of the large variation in its pharmacokinetic properties and a progressive decrease in dose requirements. An indicator for estimating the target minimum whole-blood tacrolimus concentration (Cm~ n TAC) would be useful to minimize the number of blood samplings required for tacrolimus TDM.
INTRODUCTION
Tacrolimus, a macrolide lactone, is an immunosuppressive agent that inhibits the signal-transduction pathway that leads to T-lymphocyte activation. 1-3 Tacrolimus has been used for preventing or treating graft rejection after organ transplantation. 4~ Therapeutic drug monitoring (TDM) is essential to minimizing toxicity while maintaining the efficacy of immunosuppressants such as tacrolimus, which has high variability in its pharmacokinetic (PK) properties. 7-9 In the TDM of tacrolimus, the most widely used indicator is minimum whole-blood tacrolimus concentration (Cmi n TAC). 1° TO maintain target Cmi n TAC' TDM must be performed frequently, every day until 14 postoperative days (PODs) in our institution. 11 To minimize the number of blood samplings required for tacrolimus TDM, an indicator for estimating Cm~ n TAC would be useful. In general, AUC is a useful indicator for TDM because systemic exposure is measured as AUC. Therefore, to establish the possible usefulness of a method for estimating Cm~ n TAC' we investigated the PK properties of tacrolimus in kidney transplant recipients, including AUC 0 to 9 hours after drug administration before transplantation (AUC0_9~nt) and 0 to 9 hours after drug administration and after transplantation (AUC0_9).
Previous studies have reported a progressive decrease in tacrolimus dose requirements as time after adult organ transplant recipients elapsed. 12,13 How-ever, in Japanese kidney transplant recipients, time-dependent increases in the bioavailability of tacrolimus within 4 weeks of transplantation were not found in a MEDLINE search of the literature (key terms: tacrolimus, kidney [renal] , pharmacokmetics, bioavailability [AUC] , and time after transplantation [time-dependent] ; years: 1974-2006) . If time dependent increase of blood clearance was observed in Japanese kidney transplant patients, POD might be another useful parameter for estimating Cm~ n TAC" Prednisolone, a synthetic glucocorticoid, is commonly used in the treatment of a variety of inflammatory diseases such as rheumatism, hepatitis, and nephritis. After kidney transplantation, prednisolone is used concomitantly with tacrolimus or cyclosporin A in immunosuppressive therapy in all cases of kidney transplantation in our institution. 14 Adverse events (AEs) associated with the use of prednisolone include nontraumatic, glucocorticoid-induced necrosis of the femoral head. About 6% of kidney transplant recipient's nontraumatic, glucocorticoid-induced necrosis of the femoral head was developed in our institution. 15 Despite using the same protocol for prednisolone administration, studies in adult kidney transplant recipients have found different clinical courses of this disorder, indicating individual differences in steroid sensitivity. 16 Prednisolone and tacrolimus are metabolized by the same isoenzyme--cytochrome P450 (CYP) 3A4.17,18 Competitive inhibition has been reported with combination treatment with these 2 drugs. 18 Both drugs are a substrate of P-glycoprotein, a transporter that plays an important role in drug absorption and distribution. Therefore, it is hypothesized that tacrolimus and prednisolone have a similar absorption and clearance rate in the body. In addition, the bioavailability of prednisolone is almost 100%, 19-21 with the result that plasma prednisolone concentrations per dose reflect prednisolone clearance. Prednisolone is typically administered as a fixed-dose regimen in transplant recipients in our institution. 14 For this reason, and because tacrolimus has the same elimination pathway and large variations in bioavailability, we hypothesized that plasma prednisolone concentrations might serve as an indicator of tacrolimus TDM in patients receiving immunosuppressive regimens after transplantation, and that the risks for AEs associated with prednisolone use can be estimated using tacrolimus TDM.
The primary objective of this study was to investigate whether plasma prednisolone concentration is a useful indicator of tacrolimus TDM. The secondary objective was to determine whether Cm~ n TAC is useful as an indicator of the development of nontraumatic, glucocorticoid-induced necrosis of the femoral head.
PATIENTS AND METHODS
This open-label, nonrandomized, retrospective cohort study was conducted at the Department of Transplantation and Regenerative Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan. The study protocol was approved by the ethics committee at the university, and informed consent was obtained from all patients or their legal guardians (for patients aged <18 years).
Study Population
Data from the medical records of Japanese patients (43 male and 22 female; mean age, 38 years [range, 9-64 years]) who had received a living-related kidney transplant at the university from 2001 to 2004 were included. All patients who had been administered tacrolimus treatment as described earlier were retrospectively enrolled in the study.
To investigate the relationship between the PK properties of tacrolimus and plasma prednisolone concentration, the patients for whom these data were available were included in this subanalysis.
Immunosuppressive Regimen
The following immunosuppressive regimen, developed by the Department of Transplantation and Regenerative Surgery for use after living-related kidney transplantation, was used in the patients. The initial dose of tacrolimus (0.3 mg. kg -1 • d -1) was administered orally for 2 days before transplantation. Tacrolimus (0.1 mg • kg -1 • d -1) was administered by continuous IV infusion on the day of transplantation before surgery, followed by oral tacrolimus (0.3 mg/kg BID) for 3 weeks. The dose of tacrolimus was adjusted based on the results of Cm~ n TAC monitoring empirically. Target Cm~ n TAC was 10 to 15 ng/mL. Methylprednisolone 500 mg was administered by continuous IV infusion on the day of transplantation before surgery, followed by prednisolone 50 mg/d on PODs 0 to 3 and prednisolone 40 mg/d on PODs 4 to 11. On PODs 12 to 19, the dose of prednisolone was decreased to 30 mg/d, and subsequently reduced by 5 mg each week until a dose of 10 mg/d was reached. On POD 21, azathioprine (0.50-0.75 mg/kg PO BID) or mycophenolate mofetil (10.0-12.5 mg/kg PO BID) was added to the regimen. This was continued until the patient was discharged from the hospital.
Pharmacokinetic Assessment of Tacrolimus
For PK studies of tacrolimus, blood samples were obtained 2 days before transplantation and at 0, 1, 2, 3, 4, 6, and 9 hours after drug administration on PODs 14, 21, and 28. PK parameters (eg, AUC0_ 9, Cm~, Tm~ ) were determined from those data. To determine Cmi n TAC' blood samples were obtained before drug administration each day through POD 14. After POD 14, blood samples were obtained before drug administration every other day until POD 28. Blood tacrolimus concentration was measured using microparticle enzyme immunoassay (IMx system, Abbott Laboratories, Abbott Park, Illinois). 22 AUC0_ 9 and AUC0_9int were calculated using the trapezoidal rule.
Plasma Prednisolone Concentration
Plasma prednisolone concentration was measured using the high-performance liquid chromatography (HPLC) method described by Rose and Jusko, 23 of which internal standard, the mobile phase, and organic sorbent for liquid-liquid extraction were modified by us. Plasma samples for the determination of prednisolone concentration were collected before oral administration of prednisolone 40 mg/d on PODs 4 to 11. More than 3 blood samples (2 mL) were obtained between PODs 4 to 11 from each patient, and the mean prednisolone concentration was calculated and considered as an indicator of prednisolone clearance at an early stage of prednisolone treatment (Cm~" values of prednisolone at dose of 40 mg on PODs 4-11 [Cmi" PSL40])" The prednisolone and carbamazepine used as internal standards were purchased from Nacalai Tesque, Kyoto, Japan. Acetonitrile and methanol were HPLC grade; all other reagents were reagent grade. The preparation of plasma samples was based on liquid-liquid extraction with dichloromethane. The compounds were separated on a cyanopropyl column using acetonitrile-methanol-water (66:17:17, v/v) as the mobile phase. UV detection was used at a wavelength of 254 nm. The HPLC system (Shimadzu Corporation, Kyoto, Japan) consisted of an LC-10A liquid delivery module, an SPD-10A UV detector, a CTO-10A column oven, and a Simpac CLC-CN column (150 mm × 6 mm; interior diameter, 5 1Jm). Samples were injected using an SIL-10A automatic injector. The system was controlled with an SCL-10A system controller. The area under each objective peaks in chromatograph were calibrated with a Shimadzu CR-8A data processor. The standard curves of prednisolone ranging from 0.01 to 500 1Jg/mL were considered linear. CV values (%) of inter-and intra-assay reproducibility were <10%.
Tacrolimus Concentration as an Indicator of Prednisolone Adverse Events
To investigate whether blood tacrolimus concentration might be useful as an indicator of the development of AEs associated with prednisolone use, the relationship between tacrolimus bioavailability in patients with and without nontraumatic, glucocorticoid-induced necrosis of the femoral head was investigated using the tacrolimus dose required to maintain the target (10-15 ng/mL) Cmi. TAC (d°se/C10-15) as the indicator of bioavailability. This subanalysis used data from patients diagnosed with nontraumatic, steroid-induced necrosis of the femoral head (diagnosed according to the criteria of the Research Committee of the Ministry of Health and Welfare of Japan24); data from the remaining patients were used as references.
Statistical Analysis
The correlations between Cm~" TAC or AUC0_ 9 and tacrolimus dose, Cm~, or Tm~ were determined. After POD 14, dose/C10_l 5 was considered an indicator of bioavailability. The relationship between POD and dose/C10_l 5 was investigated. The correlations between dose/C10_15, POD, and AUC0_9int were determined using the following method. Study patients were assigned to 1 of 3 AUC0_9int groups: low, medium, and high (<93, ___93--<152, and ___152 ng• h/mL, respectively). On days 6 to 10, 11 to 15, 16 to 20, 21 to 25, 26 to 30, 31 to 35, and 36 to 40, differences in mean dose/C10_l 5 in each period between the 3 AUC0_9int groups were examined using 1-way analysis of variance. To investigate whether POD, AUC0_9int , and/or plasma prednisolone concentrations are useful as an indicator of tacrolimus TDM, the correlations between Cmh ~ TAC' POD, tacrolimus dose, prednisolone dose, AUC0_9int , and Cm~ n PSL40 were determined using Pearson correlation. To assess the relative effects of each parameter on Cm~n TAC' stepwise multiple linear regressions were performed using POD, tacrolimus dose, prednisolone dose, Cm~ n PSL40' and AUC0_9int as independent variables.
Differences in dose/C10_15 between the groups with and without nontraumatic, steroid-induced necrosis of the femoral head for 5 periods of time (PODs 16-20, 21-25, 26-30, 31-35, and 36-40) were determined using the Student t test.
Analyses in this study were conducted using the StatView software package version 5.0 (SAS Institute Inc., Cary, North Carolina).
RESULTS

Pharmacokinetic Properties of Tacrolimus
The PK analysis of tacrolimus included 13 patients from whom these data were available (7 males, 6 females; range, 9-62 years). Figure 1 shows AUC0_ 9 of tacrolimus at various doses on PODs 14, 21, and 28. Although there was a large variation in the dose of tacrolimus (0.15-0.30 mg/kg), no significant differences in mean AUC0_ 9 were found between the 3 time points. Similarly, no significant differences in mean AUC0_ 9 were found between mean doses (0.30, 0.25, 0.20, and 0.15 mg/kg) on PODs 14, 21, and 28. Table I shows the correlations between the values of AUC0_ 9 and Cm~ n TAC for Cm~, Tm~, amount (mg), and dose (mg/kg) on PODs 14, 21, and 28. At all time points, AUC0_ 9 was significantly correlated with Cm~ (r = 0.829, 0.925, and 0.904, respectively; all, P ~ 0.001), and Cm~ n TAC was significantly correlated with AUC0_ 9 (r = 0.881, 0.822, and 0.886, respectively; all, P < 0.001) and Cm~ (r = 0.636, 0.621, and 0.797, respectively; P ~ 0.01, P ~ 0.01, and P ~ 0.001, respectively). Neither AUC0_ 9 nor Cm~n TAC was significantly associated with values of Tm~, amount, or dose.
The relationship between POD and dose/C10_15 as an indicator of bioavailability on POD 14 to 40 is shown in Figure 2 . As time after transplantation increased, the dose/C10_15 decreased gradually (r = -0.830; P < 0.001). 
M e a n (SD) AUC 0 t o 9 hours (AUC0_9) a f t e r a d m i n i s t r a t i o n of v a r i o u s doses of t a c r o l i m u s on p o s t o p e r a t i v e days (PODs) 14, 21
, and 28 in Japanese kidn e y t r a n s p l a n t r e c i p i e n t s (N = 65). No s i g n i f i c a n t b e t w e e n -g r o u p differences w e r e f o u n d . D a t a w e r e u n a v a i l a b l e f o r t h e 0 . 
Relationship Between Plasma Prednisolone Concentration and Tacrolimus Pharmacokinetic Properties
Cmin PSL40 obtained from the 13 patients from w h o m data were available varied from 19.5 to 161.4 ng/mL (mean [SD], 56.1 [42.3] ng/mL). The correlations between Cmi n TAC and POD; tacrolimus dose, prednisolone dose, AUC0_9int, and Cmin PSL40; and between Cmi n PSL40 and AUC0_gint are shown in Table II . Cmi n TAC was significantly negatively correlated with POD (r = -0.327; P < 0.001) and significantly positively correlated with AUC0_gint (r = 0.554) and Cmi n PSL40 (r = 0.336) (both, P < 0.001). Cm~ n TAC was not significantly associated with the tacrolimus or prednisolone dose. Cmi n PSL40 was significantly correlated with AUC0_9int (r = 0.445; P < 0.001). Cmi n TAC was used as a d e p e n d e n t variable in stepwise multiple linear regressions that were performed. Four variables (POD, prednisolone dose, Cmi n PSL40' and AUC0_9int ) were selected and entered into the regression equation (Table llI) . AUC0 9 = AUC 0 to 9 hours after drug administration and after transplantation; POD = postoperative day; Cmi n TAC = minimum whole-blood tacrolimus concentration. *P < 0.001. tp < 0.01.
Relationship Between Dose/Clo_l 5 and Nontraumatic, Steroid-Induced Necrosis of the Femoral Head
The subanalysis of necrosis included 6 patients (4 males, 2 females; mean age, 33 years [range, 21-47 years]) with a diagnosis of nontraumatic, steroidinduced necrosis of the femoral head; data from the remaining 59 patients were used as references. Figure 4 shows the comparison of mean dose/C10_l 5 between the groups with and without nontraumatic, steroid-induced necrosis of the femoral head on PODs 16 to 20, 21 to 25, 26 to 30, 31 to 35, and 36 to 40. In each period, the mean dose/C10_15 of the group that had steroid-induced necrosis of the femoral head was higher (___0.189 mg • kg -1 • d -1) than that of the group that did not have one (-0.122 mg. kg-1. d-l). Statistically significant differences were observed between the 2 groups in each period (all, P < 0.01). In both groups, mean dose/C10_15 gradually decreased with POD.
DISCUSSION
Tacrolimus treatment requires regular TDM because of its narrow therapeutic range of blood concentration and large variability in PK properties. A strong correlation between systemic exposure, AUC, and Cm~" TAC has been reported in patients who have undergone liver, kidney, and bone marrow transplantation. 25 Cm~. TAC was significantly correlated with AUC0_ 9 (r = 0.822-0.886) in this study, suggesting that Cm~" TAC was a good indicator for tacrolimus TDM, reflecting a pharmacologic efficacy. On the other hand, AUC0_ 9 was not found to be signifi- cantly correlated with amount or dose. Consequently, a patient's weight might not be a useful indicator of dose requirements. The bioavailability of tacrolimus has large inter-and intravariability (20%-809/o). 25,26 Nonlinear blood binding and a variable blood/plasma ratio have been reported to be major sources of interindividual variations in the PK properties of tacrolimus. 25 Also, tacrolimus is a substrate of P-glycoprotein and CYP 3A4. In both proteins, the induction or inhibition and the change in activation caused by drug interactions are well known. Relationships between the polymorphisms of the CYP 3A4/5 or multidrug resistance-1 gene and the tacrolimus required dose to achieve adequate blood concentration have also been found. 27 In this study, although the tacrolimus dose varied substantially (0.15-0.30 mg/kg), no significant changes in mean AUC0_ 9 were associated with the level of Cm~ . TAC" Subsequently, tacrolimus TDM must be performed frequently. 28 In this study, to obtain useful information for revising the dosing regimen after kidney transplantation, we investigated the change in the bioavailabil- ity of tacrolimus in the course of immunosuppressive therapy. After transplantation, mean dose/C10_15 decreased (ie, bioavailability increased). Moreover, a significant negative correlation between Cm~ n TAC and POD (r = -0.327; P ~ 0.001) was found. These results suggest that POD is a good indicator for estimating Cm~ n TAC" The reasons hypothesized for increased bioavailability were as follows: (1) tacrolimus absorption increased with the recovery of gastrointestinal function; (2) bile secretion increased with increased food intake; and (3) clearance of tacrolimus decreased with increasing serum proteinbinding ratio because of increasing serum albumin concentration with the recovery of kidney function.
AUC0_9int is useful for individualizing dosing regimens before transplantation. In the low-AUC0_9int group, mean dose/C10_15 was higher than that in the other groups in all periods after transplantation, suggesting that patients with low AUC0_9int needed higher doses of tacrolimus compared with patients in the highor middle-AUC0_9~nt group. In addition, Cmh ~ TAC was positively correlated with AUC0_9int @ = 0.554; P~ 0.001), suggesting that the important factors for estimating Cmi n TAC were POD and AUC0_9int.
On the other hand, it is possible that tacrolimus has PK properties similar to those of prednisolone in vivo, as previously hypothesized. Values of AUC0_9int and Cmh ~ TAC were significantly correlated with Cm~ n PSL40 in this particular study (r = 0.445 and 0.336, respectively; both, P < 0.001). At Kyoto Prefectural University of Medicine, prednisolone is administered as a fixed regimen at a relatively high dose (40 mg/d) until 11 days after transplantation. We hypothesized that Cm~ n PSL40 would reflect prednisolone clearance and would be a useful indicator of tacrolimus TDM. The results of multiple linear regressions also suggest that the most important factors for estimating Cm~ n TAC were POD, AUC0_9int , and Cmh ~ PSL40" TDM of prednisolone using plasma concentration as an indicator was not found to be useful, perhaps because of the unclear relationship between plasma prednisolone concentration and its therapeutic effects. Therefore, plasma prednisolone concentration is not commonly determined. However, our results suggest that the assessment of plasma prednisolone concentration might be a useful indicator of tacrolimus TDM. However, standards need to be established for measuring tacrolimus AUC before transplantation and determining plasma prednisolone concentration at an early stage after transplantation.
Types of nontraumatic necrosis of the femoral head include aseptic and ischemic necrosis. The mechanism by which necrosis develops is unknown, but accumulated statistical data have identified treatment with glucocorticoid, such as prednisolone, as a relevant risk factor. It is notable that the nontraumatic, steroid-induced type of necrosis of the femoral head accounts for a large percentage of cases of this disease. It has been reported that about 60% of nontraumatic necrosis of the femoral head was glucocorticoid-induced. 29 Mean dose/Clo_l 5 in the group with necrosis was lower than that in the group without necrosis. It is considered that the bioavailability of tacrolimus was high in the group with necrosis, suggesting prednisolone clearance might be low after transplantation. Therefore, tacrolimus TDM might be useful for estimating the risk for nontraumatic necrosis of the femoral head. In addition, prednisolone was administered as a fixed-dose regimen, although Cm~ n PSL40 varied substantially (19.5-161.4 ng/mL). Therefore, in determining the risk for nontraumatic necrosis of the femoral head, dose/C10_15 of tacrolimus was found to be useful as an indicator of prednisolone clearance. On the other hand, from the beginning of glucocorticoid treatment, nontraumatic necrosis of the femoral head should be prevented. 3°
In this study, AUC0_9int was found to be significantly correlated with Cmh ~ PSL40 (r = 0.445; P < 0.001), reflecting prednisolone clearance in the early post transplantation stage and suggesting that AUC0_9int might be a useful indicator for estimating the risk for steroid-induced necrosis of the femoral head, although the usefulness of this parameter is limited by the need for a measurement of tacrolimus AUC before transplantation. Another limitation of this study was its small sample size. Additional research in a larger population is needed.
CONCLUSIONS
The results of this small, retrospective study suggest that Cm~ n PSL40' AUC0-9int, and POD were significant predictors of Cm~ n TAC" These parameters were found to be a useful indicator of tacrolimus TDM in these Japanese kidney transplant recipients. Our results also suggest that dose/C10_15 and AUC0_9int might be useful indicators for estimating the risk for nontraumatic, steroid-induced necrosis of the femoral head.
